LICENSE AGREEMENT PREAMBLELicense Agreement • February 28th, 2014 • Salix Pharmaceuticals LTD • Pharmaceutical preparations • New York
This LICENSE AGREEMENT (the “Agreement”) is entered into as of the 30th day of November, 2007 (the “Effective Date”) by and between Santarus, Inc., a Delaware corporation, with its principal place of business at 10590 West Ocean Air Drive, Suite 200, San Diego, CA 92130 (“Santarus”) and Glaxo Group Limited, an English company with its principal place of business at 40 Berkeley Avenue Greenford Middlesex United Kingdom on behalf of itself and its Affiliates (together “GSK”). Santarus and GSK are sometimes referred to herein collectively as the “Parties” and separately as a “Party.”
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT (INDICATED BY ASTERISKS) HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT UNDER 17 AND 230.406. EXCLUSIVE...Exclusive License Agreement • February 28th, 2014 • Salix Pharmaceuticals LTD • Pharmaceutical preparations • California
This Exclusive License Agreement (“Agreement”) is effective as of the 26th day of January 2001 (the “Effective Date”), by and between THE CURATORS OF THE UNIVERSITY OF MISSOURI, a public corporation organized under the laws of Missouri, having a principal place of business at 615 Locust Street Building, Third Floor, Columbia, Missouri 65211-1400 (“the University”), and SANTARUS, INC. (“Santarus”), a California corporation, having a principal place of business at 12230 El Camino Real, Suite 300, San Diego, California 92130.
